Pathogenesis of Pneumococci Infection

 

 

Pathogenesis

 

Pneumococci is the causative agent of pneumococcal pneumonia. It is often multilobar in nature. Pneumococcal pneumonia develops most often during the course of viral infections of the upper respiratory tract. Complications of pneumococcal pneumonia include empyema, pleurisy, and pericarditis. Pneumococcus is also comonly found in excerbations of COAD. Pneumococcal pneumonia develops most often during the course of viral infections of the upper respiratory tract. Pneumococcal pneumonia is often multilobar. Primary pneumococcal diseases of the upper respiratory tract include sinusitis and otitis media. Progressive infections of the mastoid or paranasal sinuses sometimes extend directly into the subarachnoid space to cause pneumococcal menigitis.

 

 

Diagnosis

 

A tentative diagnosis of pneumococcal pneumonia may be made rapidly by examining the patientís sputum by gram-stain. The bacterium is readily cultured on blood agar plates. Because many healthy humans carry pneumococci in their throats, the demonstration of the organism in sputum or pharyngeal culture does not provide conclusive evidence of pneumococcal infection. Recovery of pneumococci from the patientís blood, on the other hand is diagnostic. Therefore, blood should be obtained before the commencement of antibiotic therapy . Other bodily fluids should be cultured in the same way and also on blood agar. Pneumococci are morphologically similar to other streptococci of the viridans group but they differ in being bile-soluble and sensitive to optochin.

 

 

Treatment

 

In the past, patients used to be treated with type-specific antiserum but these are no longer used. Benzylpenicillin is the drug of choice although resistance to this agent is found occasionally, being due to mutations in its penicillin-binding proteins. Erthromycin or clindamycin may be used to treat pneumonia in patients with known hypersensitivity to penicillin.

 

 


Prevention

 

A pneucoccal vaccine consisting of 23 capsular Ags is now available, and its administration† to individuals at high risk of serious/fatal infections is recommended. Such individuals include the elderly and individuals with debilitating diseases.